Mirum Pharmaceuticals ( (MIRM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mirum Pharmaceuticals’ stock has been positively influenced by strong Q2 earnings and promising studies on volixibat, which have led to increased price targets. The company’s strategic moves, including the completion of enrollment in the VISTAS study and filing for a mixed securities shelf, signal growth and capital raising plans. Despite insider selling, analysts remain optimistic due to the company’s promising drug developments and unique position in the biotech sector.
More about Mirum Pharmaceuticals
YTD Price Performance: 80.76%
Average Trading Volume: 612,419
Technical Sentiment Signal: Buy
Current Market Cap: $3.82B
For further insights into MIRM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.